Targeting neoantigens to augment antitumour immunity

被引：434

作者：

Yarchoan, Mark ^{[1
]}

Johnson, Burles A., III ^{[1
]}

Lutz, Eric R. ^{[1
]}

Laheru, Daniel A. ^{[1
]}

Jaffee, Elizabeth M. ^{[1
]}

机构：

[1] Johns Hopkins, Ctr Comprehens Canc, Baltimore, MD 21231 USA

来源：

NATURE REVIEWS CANCER | 2017年 / 17卷 / 04期

关键词：

PLASMACYTOID DENDRITIC CELLS; CYTOLYTIC T-LYMPHOCYTES; GROWTH-FACTOR RECEPTOR; PD-1; BLOCKADE; CANCER-IMMUNOTHERAPY; CHECKPOINT BLOCKADE; INDOLEAMINE 2,3-DIOXYGENASE; HUMAN-PAPILLOMAVIRUS; TUMOR-REGRESSION; DOSE CYTARABINE;

D O I：

10.1038/nrc.2016.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause tumours to express mutant proteins that are tumour specific and not expressed on normal cells (neoantigens). These neoantigens are an attractive immune target because their selective expression on tumours may minimize immune tolerance as well as the risk of autoimmunity. In this Review we discuss the emerging evidence that neoantigens are recognized by the immune system and can be targeted to increase antitumour immunity. We also provide a framework for personalized cancer immunotherapy through the identification and selective targeting of individual tumour neoantigens, and present the potential benefits and obstacles to this approach of targeted immunotherapy.

引用

页码：209 / 222

页数：14

共 164 条

[1]

Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies [J].

Aleksic, Milos ;

Liddy, Nathaniel ;

Molloy, Peter E. ;

Pumphrey, Nick ;

Vuidepot, Annelise ;

Chang, Kyong-Mi ;

Jakobsen, Bent K. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (12) :3174-3179

[2]

Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3]

Endocrine-responsive breast cancer and strategies for combating resistance [J].

Ali, S ;

Coombes, RC .

NATURE REVIEWS CANCER, 2002, 2 (02) :101-+

[4]

[Anonymous], J TRANSL MED SUPPL 1, DOI DOI 10.1186/1479-5876-13-S1-O5

[5]

Argani P, 2001, CLIN CANCER RES, V7, P3862

[6]

BINDING OF IMMUNOGENIC PEPTIDES TO IA HISTOCOMPATIBILITY MOLECULES [J].

BABBITT, BP ;

ALLEN, PM ;

MATSUEDA, G ;

HABER, E ;

UNANUE, ER .

NATURE, 1985, 317 (6035) :359-361

[7]

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs [J].

Bach, Peter B. ;

Pearson, Steven D. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (23) :2503-2504

[8]

Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].

Baeuerle, Patrick A. ;

Reinhardt, Carsten .

CANCER RESEARCH, 2009, 69 (12) :4941-4944

[9]

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors [J].

Baird, Jason R. ;

Friedman, David ;

Cottam, Benjamin ;

Dubensky, Thomas W., Jr. ;

Kanne, David B. ;

Bambina, Shelly ;

Bahjat, Keith ;

Crittenden, Marka R. ;

Gough, Michael J. .

CANCER RESEARCH, 2016, 76 (01) :50-61

[10]

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

← 1 2 3 4 5 6 7 8 9 10 →